CHARLOTTE, N.C., Sept. 2, 2008 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it has initiated patient dosing in Study 301, the second of two pivotal Phase III trials designed to demonstrate efficacy and support U.S. marketing approval of Droxidopa in neurogenic orthostatic hypotension (NOH).
